Illinois General Assembly - Full Text of HB1660
Illinois General Assembly

Previous General Assemblies

Full Text of HB1660  99th General Assembly

HB1660ham002 99TH GENERAL ASSEMBLY

Rep. Michael P. McAuliffe

Filed: 4/14/2015

 

 


 

 


 
09900HB1660ham002LRB099 06684 JLK 32073 a

1
AMENDMENT TO HOUSE BILL 1660

2    AMENDMENT NO. ______. Amend House Bill 1660 by replacing
3everything after the enacting clause with the following:
 
4    "Section 5. The Department of Public Health Powers and
5Duties Law of the Civil Administrative Code of Illinois is
6amended by changing Section 2310-675 as follows:
 
7    (20 ILCS 2310/2310-675)
8    (Section scheduled to be repealed on January 1, 2016)
9    Sec. 2310-675. Hepatitis C Task Force.
10    (a) The General Assembly finds and declares the following:
11        (1) Viral hepatitis is a contagious and
12    life-threatening disease that has a substantial and
13    increasing effect upon the lifespans and quality of life of
14    at least 5,000,000 persons living in the United States and
15    as many as 180,000,000 worldwide. According to the U.S.
16    Department of Health and Human Services (HHS), the chronic

 

 

09900HB1660ham002- 2 -LRB099 06684 JLK 32073 a

1    form of the hepatitis C virus (HCV) and hepatitis B virus
2    (HBV) account for the vast majority of hepatitis-related
3    mortalities in the U.S., yet as many as 65% to 75% of
4    infected Americans remain unaware that they are infected
5    with the virus, prompting the U.S. Centers for Disease
6    Control and Prevention (CDC) to label these viruses as the
7    silent epidemic. HCV and HBV are major public health
8    problems that cause chronic liver diseases, such as
9    cirrhosis, liver failure, and liver cancer. The 5-year
10    survival rate for primary liver cancer is less than 5%.
11    These viruses are also the leading cause of liver
12    transplantation in the United States. While there is a
13    vaccine for HBV, no vaccine exists for HCV. However, there
14    are anti-viral treatments for HCV that can improve the
15    prognosis or actually clear the virus from the patient's
16    system. Unfortunately, the vast majority of infected
17    patients remain unaware that they have the virus since
18    there are generally no symptoms. Therefore, there is a dire
19    need to aid the public in identifying certain risk factors
20    that would warrant testing for these viruses. Millions of
21    infected patients remain undiagnosed and continue to be at
22    elevated risks for developing more serious complications.
23    More needs to be done to educate the public about this
24    disease and the risk factors that warrant testing. In some
25    cases, infected patients play an unknowing role in further
26    spreading this infectious disease.

 

 

09900HB1660ham002- 3 -LRB099 06684 JLK 32073 a

1        (2) The existence of HCV was definitively published and
2    discovered by medical researchers in 1989. Prior to this
3    date, HCV is believed to have spread unchecked. The
4    American Association for the Study of Liver Diseases
5    (AASLD) recommends that primary care physicians screen all
6    patients for a history of any viral hepatitis risk factor
7    and test those individuals with at least one identifiable
8    risk factor for the virus. Some of the most common risk
9    factors have been identified by AASLD, HHS, and the U.S.
10    Department of Veterans Affairs, as well as other public
11    health and medical research organizations, and include the
12    following:
13            (A) anyone who has received a blood transfusion
14        prior to 1992;
15            (B) anyone who is a Vietnam-era veteran;
16            (C) anyone who has abnormal liver function tests;
17            (D) anyone infected with the HIV virus;
18            (E) anyone who has used a needle to inject drugs;
19            (F) any health care, emergency medical, or public
20        safety worker who has been stuck by a needle or exposed
21        to any mucosal fluids of an HCV-infected person; and
22            (G) any children born to HCV-infected mothers.
23        A 1994 study determined that Caucasian Americans
24    statistically accounted for the most number of infected
25    persons in the United States, while the highest incidence
26    rates were among African and Hispanic Americans.

 

 

09900HB1660ham002- 4 -LRB099 06684 JLK 32073 a

1        (3) In January of 2010, the Institute of Medicine
2    (IOM), commissioned by the CDC, issued a comprehensive
3    report entitled Hepatitis and Liver Cancer: A National
4    Strategy for Prevention and Control of Hepatitis B and C.
5    The key findings and recommendations from the IOM's report
6    are (A) there is a lack of knowledge and awareness about
7    chronic viral hepatitis on the part of health care and
8    social service providers, (B) there is a lack of knowledge
9    and awareness about chronic viral hepatitis among at-risk
10    populations, members of the public, and policy makers, and
11    (C) there is insufficient understanding about the extent
12    and seriousness of the public health problem, so inadequate
13    public resources are being allocated to prevention,
14    control, and surveillance programs.
15        (4) In this same 2010 IOM report, researchers compared
16    the prevalence and incidences of HCV, HBV, and HIV and
17    found that, although there are only 1,100,000 HIV/AIDS
18    infected persons in the United States and over 4,000,000
19    Americans infected with viral hepatitis, the percentage of
20    those with HIV that are unaware they have HIV is only 21%
21    as opposed to approximately 70% of those with viral
22    hepatitis being unaware that they have viral hepatitis. It
23    appears that public awareness of risk factors associated
24    with each of these diseases could be a major factor in the
25    alarming disparity between the percentage of the
26    population that is infected with one of these blood

 

 

09900HB1660ham002- 5 -LRB099 06684 JLK 32073 a

1    viruses, but unaware that they are infected.
2        (5) In light of the widely varied nature of the risk
3    factors mentioned in this subsection (a), the previous
4    findings by the Institute of Medicine, and the clear
5    evidence of the disproportional public awareness between
6    HIV and viral hepatitis, it is clearly in the public
7    interest for this State to establish a task force to gather
8    testimony and develop an action plan to (A) increase public
9    awareness of the risk factors for these viruses, (B)
10    improve access to screening for these viruses, and (C)
11    provide those infected with information about the
12    prognosis, treatment options, and elevated risk of
13    developing cirrhosis and liver cancer. There is clear and
14    increasing evidence that many adults in Illinois and in the
15    United States have at least one of the risk factors
16    mentioned in this subsection (a).
17        (6) The General Assembly also finds that it is in the
18    public interest to bring communities of Illinois-based
19    veterans of American military service into familiarity
20    with the issues created by this disease, because many
21    veterans, especially Vietnam-era veterans, have at least
22    one of the previously enumerated risk factors and are
23    especially prone to being affected by this disease; and
24    because veterans of American military service should enjoy
25    in all cases, and do enjoy in most cases, adequate access
26    to health care services that include medical management and

 

 

09900HB1660ham002- 6 -LRB099 06684 JLK 32073 a

1    care for preexisting and long-term medical conditions,
2    such as infection with the hepatitis virus.
3    (b) There is established the Hepatitis C Task Force within
4the Department of Public Health. The purpose of the Task Force
5shall be to:
6        (1) develop strategies to identify and address the
7    unmet needs of persons with hepatitis C in order to enhance
8    the quality of life of persons with hepatitis C by
9    maximizing productivity and independence and addressing
10    emotional, social, financial, and vocational challenges of
11    persons with hepatitis C;
12        (2) develop strategies to provide persons with
13    hepatitis C greater access to various treatments and other
14    therapeutic options that may be available; and
15        (3) develop strategies to improve hepatitis C
16    education and awareness.
17    (c) The Task Force shall consist of 17 members as follows:
18        (1) the Director of Public Health, the Director of
19    Veterans' Affairs, and the Director of Human Services, or
20    their designees, who shall serve ex officio;
21        (2) ten public members who shall be appointed by the
22    Director of Public Health from the medical, patient, and
23    service provider communities, including, but not limited
24    to, HCV Support, Inc.; and
25        (3) four members of the General Assembly, appointed one
26    each by the President of the Senate, the Minority Leader of

 

 

09900HB1660ham002- 7 -LRB099 06684 JLK 32073 a

1    the Senate, the Speaker of the House of Representatives,
2    and the Minority Leader of the House of Representatives.
3    Vacancies in the membership of the Task Force shall be
4filled in the same manner provided for in the original
5appointments.
6    (d) The Task Force shall organize within 120 days following
7the appointment of a majority of its members and shall select a
8chairperson and vice-chairperson from among the members. The
9chairperson shall appoint a secretary, who need not be a member
10of the Task Force.
11    (e) The public members shall serve without compensation and
12shall not be reimbursed for necessary expenses incurred in the
13performance of their duties, unless funds become available to
14the Task Force.
15    (f) The Task Force shall be entitled to call to its
16assistance and avail itself of the services of the employees of
17any State, county, or municipal department, board, bureau,
18commission, or agency as it may require and as may be available
19to it for its purposes.
20    (g) The Task Force may meet and hold hearings as it deems
21appropriate.
22    (h) The Department of Public Health shall provide staff
23support to the Task Force.
24    (i) The Task Force shall report its findings and
25recommendations to the Governor and to the General Assembly,
26along with any legislative bills that it desires to recommend

 

 

09900HB1660ham002- 8 -LRB099 06684 JLK 32073 a

1for adoption by the General Assembly, no later than December
231, 2015.
3    (j) The Task Force is abolished and this Section is
4repealed on January 1, 2017 2016.
5(Source: P.A. 98-493, eff. 8-16-13; 98-756, eff. 7-16-14.)".